These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8981015)

  • 21. Late-onset medullary carcinoma of the thyroid: need for genetic testing and prophylactic thyroidectomy in adult family members.
    Shaha AR; Cohen T; Ghossein R; Tuttle RM
    Laryngoscope; 2006 Sep; 116(9):1704-7. PubMed ID: 16955009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic thyroidectomy in the treatment of thyroid medullary carcinoma. Age for surgery?
    Hassett S; Costigan C; McDermott M; Fitzgerald RJ
    Eur J Pediatr Surg; 2000 Oct; 10(5):334-6. PubMed ID: 11194546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).
    Romei C; Cosci B; Renzini G; Bottici V; Molinaro E; Agate L; Passannanti P; Viola D; Biagini A; Basolo F; Ugolini C; Materazzi G; Pinchera A; Vitti P; Elisei R
    Clin Endocrinol (Oxf); 2011 Feb; 74(2):241-7. PubMed ID: 21054478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results and follow-up in eleven MEN 2A gene carriers after prophylactic thyroidectomy.
    Frank-Raue K; Höppner W; Buhr H; Herfarth C; Raue F
    Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 4():76-8. PubMed ID: 9439923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families.
    Wion-Barbot N; Schuffenecker I; Niccoli P; Conte-Devolx B; Lecomte P; Houdent C; Bigorgne JC; Modigliani E
    Ann Endocrinol (Paris); 1997; 58(4):302-8. PubMed ID: 9436479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family.
    Lips CJ; Landsvater RM; Höppener JW; Geerdink RA; Blijham GH; Jansen-Schillhorn van Veen JM; Feldberg MA; van Gils AP; Hoogenboom H; Berends MJ
    J Intern Med; 1995 Oct; 238(4):347-56. PubMed ID: 7595171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for multiple endocrine neoplasia type 2a with DNA-polymorphism analysis.
    Sobol H; Narod SA; Nakamura Y; Boneu A; Calmettes C; Chadenas D; Charpentier G; Chatal JF; Delepine N; Delisle MJ
    N Engl J Med; 1989 Oct; 321(15):996-1001. PubMed ID: 2571086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presymptomatic detection and treatment of Japanese carriers of the multiple endocrine neoplasia type 2A gene.
    Uchino S; Noguchi S; Sato M; Adachi M; Yamashita H; Watanabe S; Murakami T; Toda M; Murakami N; Yamashita H
    Surg Today; 1999; 29(9):862-7. PubMed ID: 10489126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial thyroid cancer.
    Alsanea O; Clark OH
    Curr Opin Oncol; 2001 Jan; 13(1):44-51. PubMed ID: 11148685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presymptomatic screening for medullary thyroid carcinoma in patients with multiple endocrine neoplasia type 2A.
    Frilling A; Röher HD; Ponder BA
    World J Surg; 1994; 18(4):577-81; discussion 581-2. PubMed ID: 7725747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hereditary thyroid cancer].
    Dralle H; Machens A; Lorenz K
    Chirurg; 2008 Nov; 79(11):1017-28. PubMed ID: 18818894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inherited medullary thyroid cancer and the duty to warn: revisiting Pate v. Threlkel in light of HIPAA.
    Rosenthal MS; Pierce HH
    Thyroid; 2005 Feb; 15(2):140-5. PubMed ID: 15753673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-cell hyperplasia and medullary thyroid microcarcinoma.
    Albores-Saavedra JA; Krueger JE
    Endocr Pathol; 2001; 12(4):365-77. PubMed ID: 11914470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population-based study of familial medullary thyroid cancer.
    Hemminki K; Dong C
    Fam Cancer; 2001; 1(1):45-9. PubMed ID: 14574015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genetic aspects of medullary thyroid carcinoma: recognition and management.
    Williamson P; Ponder B; Church S; Fiddler M; Harris R
    J R Coll Physicians Lond; 1996; 30(5):443-7. PubMed ID: 8912284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medullary thyroid carcinoma: ethical issues for the surgeon.
    Shuman AG; Shaha AR; Tuttle RM; Fins JJ; Morris LG
    Ann Surg Oncol; 2012 Jul; 19(7):2102-7. PubMed ID: 22322952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of affected MEN2A gene carriers by DNA linkage analysis for early total thyroidectomy: a progress in clinical screening program for children with hereditary cancer syndrome.
    Shimotake T; Iwai N; Yanagihara J; Tokiwa K; Tanaka N; Yamamoto M; Takai S
    J Pediatr Surg; 1992 Apr; 27(4):444-6. PubMed ID: 1355790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hereditary thyroid cancer syndromes and genetic testing.
    Rowland KJ; Moley JF
    J Surg Oncol; 2015 Jan; 111(1):51-60. PubMed ID: 25351655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: a multicentric pilot-evaluation.
    Freyer G; Dazord A; Schlumberger M; Conte-Devolx B; Ligneau B; Trillet-Lenoir V; Lenoir GM
    Ann Oncol; 1999 Jan; 10(1):87-95. PubMed ID: 10076727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of genetic screening in the management of hereditary malignancy.
    Gagel RF
    Horm Metab Res; 1993 Sep; 25(9):481-3. PubMed ID: 7901138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.